China Pharma Holdings, Inc.CPHINYSE
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank57
5Y CAGR-11.3%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-11.3%/yr
Long-term compound
Percentile
P57
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2024 | 18.27% |
| 2023 | 29.17% |
| 2022 | -41.73% |
| 2021 | -15.61% |
| 2020 | 64.59% |
| 2019 | 33.21% |
| 2018 | 90.53% |
| 2017 | -75.28% |
| 2016 | -61.95% |
| 2015 | -65.63% |